1、 Industry prospects
Research and development of new drugs is the main driving factor for the development of the global pharmaceutical industry.
According to the statistics of pharmapprojects, the number of new drugs under research in the world was 5995 in 2001, and increased to 16181 in 2019, 2.7 times of that in 2001.
The number of new drugs approved by FDA in recent years (the highest number of new drugs approved by FDA in recent years) has reached the highest level in recent years. It is estimated that the global pharmaceutical R & D investment will reach 213 billion US dollars by 2024, with an average annual compound growth rate of 3% from 2018 to 2024.
In recent years, in order to reduce the cost of new drug research and development, improve the efficiency of research and development, shorten the R & D and listing cycle, and reduce the production costs after listing, in terms of CMO / cdmo, the proportion of R & D investment in CMO / cdmo of large, medium and small pharmaceutical enterprises in the world in 2017 is 36.04%, and it is expected to increase to 52.22% by 2022;
in terms of cro, the penetration rate of global cro industry is only 18% in 2006, but by 2015 It has increased to 44% in, and is expected to further increase to 54% by 2020.
The penetration rate of customized services is increasing. In 2017, the global pharmaceutical CMO / cdmo market capacity has reached US $62.8 billion, which is expected to grow to US $102.5 billion by 2021, with an average annual compound growth rate of more than 13% from 2018 to 2021. In 2018, the global cro market size is about 48.7 billion US dollars.
It is estimated that the average annual compound growth rate will reach about 10.5% from 2018 to 2022, and the global cro market size will reach 72.7 billion US dollars by 2022.
In the field of polypeptide, there are about 200-300 kinds of polypeptide drugs in clinical trials. As of September 2018, more than 70 kinds of peptide drugs have been approved for marketing.
Polypeptide drugs are mainly used in the treatment of chronic diseases. At present, peptide drugs are mainly distributed in seven major disease treatment fields, including rare diseases, cancer, diabetes, gastrointestinal tract, orthopedics, immunity, cardiovascular diseases, etc. among them, rare diseases, cancer and diabetes are the “troika” driving the peptide drug market.
There are also many heavy varieties in the other four fields, and the representative varieties include lira Rutide, dulaglycopeptide, somaluptide, leuprorelin, tripatide, octreotide, exenatide, etc.
In 2017, the market scale of peptide preparations in China was about 1.74 billion US dollars, accounting for only 5.1% of the global peptide preparation market and 1.4% of China’s overall pharmaceutical market.
However, the sales scale of peptide preparations in the United States, five European countries and Japan reached US $20.01 billion, US $3.77 billion and US $2.02 billion respectively.
Compared with the international mature market, the sales scale of peptide preparations in China still lags far behind the mature international market. In 2016, the global market size of small molecular drugs was about 900 billion US dollars, accounting for 81% of the overall drug market.
It is expected that the market size of small molecular drugs will exceed US $1 trillion by 2020, and the average annual compound growth rate from 2018 to 2022 will reach 3.3%.
2、 Market position
In the CMO / cdmo industry, the domestic CMO / cdmo industry is relatively scattered with relatively more enterprises. Its business mainly focuses on the contract R & D and production of intermediates, APIs or preparations of small molecular chemical drugs.
In the field of polypeptide, the world’s leading enterprises in the production of polypeptide raw materials are mainly Bachem company in Switzerland and polypeptide company in the United States. Swiss Bachem company is mainly engaged in the process development and production of polypeptide raw materials and complex organic molecules.
It has nearly 50 years of polypeptide research experience. It has branches in Europe, the United States and Asia, and its business covers the world. In 2019, its sales volume exceeded 300 million US dollars. Polypeptide mainly provides proprietary and general GMP grade peptides for pharmaceutical and biotechnology companies. It has six GMP production sites in France, India, Belgium, Sweden and the United States.
In the domestic market,shengnuo biotechnology is one of the few biomedical enterprises with peptide drugs as the main research and development direction.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……